Literature DB >> 9150374

Cytotoxic action of alpha-linolenic and eicosapentaenoic acids on myeloma cells in vitro.

G Sravan Kumar1, U N Das.   

Abstract

Both alpha-linolenic (ALA) and eicosapentaenoic acids (EPA) were toxic to SP 2/0 mouse myeloma cells in vitro. On the other hand, linoleic acid (LA), gamma-linolenic acid (GLA), di-homo-gamma linolenic acid (DGLA), arachidonic acid (AA), docosahexaenoic acid (DHA) and oleic acid (OA) were much less effective in their growth suppressive actions. Both nordihydroguaiaretic acid (NDGA) and Indomethacin (IM) could block the action of the fatty acids indicating a role for prostaglandins (PGs) and leukotrienes (LTs) in the growth suppressive action of ALA and EPA. Superoxide dismutase (SOD) completely blocked, while vitamin E and reduced glutathione (GSH) could prevent to a limited extent the anti-proliferative effects of ALA and EPA. Catalase, mannitol, chlorpromazine (CPZ) and trifluoperazine (TFP) did not block the cytotoxic actions of ALA and EPA. N(G)-mono-methyl L-arginine (N(G)MMA), an analogue of L-arginine, which inhibits nitric oxide synthase, was ineffective in preventing the cytotoxicity induced by ALA and EPA. Fatty acid analysis of the various lipid fractions of SP 2/0 cells treated with ALA and EPA showed significant incorporation of these fatty acids in the cell membrane lipid pools. These results suggest that ALA and EPA induced suppression of SP 2/0 cell proliferation is cyclo-oxygenase (CO), lipoxygenase (LO) and superoxide dependent. Lipid peroxidation has only a limited role in this process. Both calmodulin dependent process and L-arginine derived nitric oxide do not seem to have a role in the cytotoxic action of ALA and EPA in these cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9150374     DOI: 10.1016/s0952-3278(97)90572-x

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  8 in total

1.  Colorectal cancer cell growth inhibition by linoleic acid is related to fatty acid composition changes.

Authors:  Xiao-feng Lu; Guo-qing He; Hai-ning Yu; Qi Ma; Sheng-rong Shen; Undurti N Das
Journal:  J Zhejiang Univ Sci B       Date:  2010-12       Impact factor: 3.066

Review 2.  Lipid metabolism in tumor microenvironment: novel therapeutic targets.

Authors:  Xingkai Liu; Ping Zhang; Jing Xu; Guoyue Lv; Yan Li
Journal:  Cancer Cell Int       Date:  2022-07-05       Impact factor: 6.429

3.  Linoleic acid suppresses colorectal cancer cell growth by inducing oxidant stress and mitochondrial dysfunction.

Authors:  Xiaofeng Lu; Haining Yu; Qi Ma; Shengrong Shen; Undurti N Das
Journal:  Lipids Health Dis       Date:  2010-09-24       Impact factor: 3.876

4.  Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma.

Authors:  Gopalakrishnan Ramakrishnan; Carmen Martha Elinos-Báez; Sundaram Jagan; Titto Alby Augustine; Sattu Kamaraj; Pandi Anandakumar; Thiruvengadam Devaki
Journal:  Mol Cell Biochem       Date:  2008-03-31       Impact factor: 3.396

Review 5.  Effects of the polyunsaturated fatty acids, EPA and DHA, on hematological malignancies: a systematic review.

Authors:  Milad Moloudizargari; Esmaeil Mortaz; Mohammad Hossein Asghari; Ian M Adcock; Frank A Redegeld; Johan Garssen
Journal:  Oncotarget       Date:  2018-02-05

Review 6.  Roles of omental and bone marrow adipocytes in tumor biology.

Authors:  Yoon Jin Cha; Ja Seung Koo
Journal:  Adipocyte       Date:  2019-12       Impact factor: 4.534

7.  Effects of polyunsaturated fatty acids on the growth of gastric cancer cells in vitro.

Authors:  Jinfeng Dai; Junhui Shen; Wensheng Pan; Shengrong Shen; Undurti N Das
Journal:  Lipids Health Dis       Date:  2013-05-10       Impact factor: 3.876

Review 8.  Omega-3 Fatty Acids and Cancer Cell Cytotoxicity: Implications for Multi-Targeted Cancer Therapy.

Authors:  Donatella D'Eliseo; Francesca Velotti
Journal:  J Clin Med       Date:  2016-01-26       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.